FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992756775> ?p ?o ?g. }

• W1992756775 endingPage "1742" @default.
• W1992756775 startingPage "1733" @default.
• W1992756775 abstract "Background. Both interleukin-2 (IL-2) and alpha-interferon (α-IFN) have some efficacy in renal cell cancer (RCC) as single agents. Additionally, there is some evidence for additive or synergistic antitumoral activity of IL-2 and α-IFN in vitro and possibly in vivo. Based on these data, the authors initiated a Phase II trial with a combination of recombinant IL-2 (rIL-2) and recombinant α-IFN (α-rIFN) in advanced RCC. Methods. Thirty-six assessable patients with metastatic RCC were entered in this Phase II trial using a daily alternating schedule of α-rIFN and rIL-2. Over a period of 14 days, the patients received daily alternating treatment with 10 × 106 IU/m2 of recombinant alpha-2b-interferon subcutaneously and 18 × 106 IU/m2 of rIL-2 as a 1-hour intravenous infusion. This treatment schedule was repeated every sixth week up to a maximum of four cycles. After the second cycle, patients were examined for response. Patients with stable disease or better received two additional cycles of therapy. Patients with progressive disease were available for other strategies. Results. Thirty-six patients entered the trial and were assessable for toxic effects. Thirty of 36 patients completed at least two cycles and were assessable for response. Nine patients achieved an objective response: 2 had complete responses (CR) and 7 had partial responses (PR). Three patients had a minor response. No effect was observed in patients with local relapse or bone metastases. A relapse-free survival length of 6 months or longer was seen in both patients with CR (12, 23+ months) and in four of seven patients with PR (6, 7, 12, 12 months). The toxicity was moderate and included fever and nausea in most patients, and hypotension, fatigue, skin rash, and arthralgia in a minority of the patients. No Grade 4 and only occasionally Grade 3 toxicity was observed. Fluid retention was negligible. The monitoring of immunologic parameters showed a significant rebound lymphocytosis including cytotoxic (CD56+) cells; in responders the peak of lymphocytosis occurred up to 1 week later than in nonresponders. Peripheral lymphocytes obtained after therapy showed only a slight increase of natural killer cell and lymphokine-activated killer cell activity. During therapy, there was a great release of secondary cytokines as tumor necrosis factor-alpha, γ-interferon, and interleukin-6, with a peak level 2–4 hours after rIL-2 infusion. Conclusions. In conclusion, daily alternating administration of α-rIFN and rIL-2 is effective in RCC with less toxicity, and the response rate is comparable to those of other immunotherapeutic schedules, including adoptive immunotherapy and combinations of high-dose IL-2 and α-IFN." @default.
• W1992756775 created "2016-06-24" @default.
• W1992756775 creator A5000499307 @default.
• W1992756775 creator A5007667130 @default.
• W1992756775 creator A5018838414 @default.
• W1992756775 creator A5023053676 @default.
• W1992756775 creator A5049195610 @default.
• W1992756775 creator A5068927061 @default.
• W1992756775 creator A5089180355 @default.
• W1992756775 date "1993-09-01" @default.
• W1992756775 modified "2023-09-27" @default.
• W1992756775 title "Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study" @default.
• W1992756775 cites W1444462873 @default.
• W1992756775 cites W1510666005 @default.
• W1992756775 cites W1552725267 @default.
• W1992756775 cites W1823165246 @default.
• W1992756775 cites W1862901090 @default.
• W1992756775 cites W1949673766 @default.
• W1992756775 cites W1971819730 @default.
• W1992756775 cites W1975568557 @default.
• W1992756775 cites W1985981664 @default.
• W1992756775 cites W1988730141 @default.
• W1992756775 cites W1991360369 @default.
• W1992756775 cites W1992000854 @default.
• W1992756775 cites W2006704738 @default.
• W1992756775 cites W2024254120 @default.
• W1992756775 cites W2025884975 @default.
• W1992756775 cites W2037104948 @default.
• W1992756775 cites W2071191803 @default.
• W1992756775 cites W2149724818 @default.
• W1992756775 cites W2155221651 @default.
• W1992756775 cites W2227053780 @default.
• W1992756775 cites W2242340339 @default.
• W1992756775 cites W2263588543 @default.
• W1992756775 cites W2270697554 @default.
• W1992756775 cites W2285002277 @default.
• W1992756775 cites W2322553446 @default.
• W1992756775 cites W2326245275 @default.
• W1992756775 cites W2395220548 @default.
• W1992756775 cites W2912006257 @default.
• W1992756775 cites W4232846723 @default.
• W1992756775 cites W4245868295 @default.
• W1992756775 cites W4248915126 @default.
• W1992756775 doi "https://doi.org/10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x" @default.
• W1992756775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8348502" @default.
• W1992756775 hasPublicationYear "1993" @default.
• W1992756775 type Work @default.
• W1992756775 sameAs 1992756775 @default.
• W1992756775 citedByCount "40" @default.
• W1992756775 countsByYear W19927567752012 @default.
• W1992756775 countsByYear W19927567752013 @default.
• W1992756775 countsByYear W19927567752015 @default.
• W1992756775 countsByYear W19927567752017 @default.
• W1992756775 crossrefType "journal-article" @default.
• W1992756775 hasAuthorship W1992756775A5000499307 @default.
• W1992756775 hasAuthorship W1992756775A5007667130 @default.
• W1992756775 hasAuthorship W1992756775A5018838414 @default.
• W1992756775 hasAuthorship W1992756775A5023053676 @default.
• W1992756775 hasAuthorship W1992756775A5049195610 @default.
• W1992756775 hasAuthorship W1992756775A5068927061 @default.
• W1992756775 hasAuthorship W1992756775A5089180355 @default.
• W1992756775 hasConcept C121608353 @default.
• W1992756775 hasConcept C126322002 @default.
• W1992756775 hasConcept C141071460 @default.
• W1992756775 hasConcept C203014093 @default.
• W1992756775 hasConcept C2776178377 @default.
• W1992756775 hasConcept C2776694085 @default.
• W1992756775 hasConcept C2777701055 @default.
• W1992756775 hasConcept C2778822529 @default.
• W1992756775 hasConcept C2781228144 @default.
• W1992756775 hasConcept C2909179924 @default.
• W1992756775 hasConcept C31760486 @default.
• W1992756775 hasConcept C43376680 @default.
• W1992756775 hasConcept C71924100 @default.
• W1992756775 hasConcept C90924648 @default.
• W1992756775 hasConceptScore W1992756775C121608353 @default.
• W1992756775 hasConceptScore W1992756775C126322002 @default.
• W1992756775 hasConceptScore W1992756775C141071460 @default.
• W1992756775 hasConceptScore W1992756775C203014093 @default.
• W1992756775 hasConceptScore W1992756775C2776178377 @default.
• W1992756775 hasConceptScore W1992756775C2776694085 @default.
• W1992756775 hasConceptScore W1992756775C2777701055 @default.
• W1992756775 hasConceptScore W1992756775C2778822529 @default.
• W1992756775 hasConceptScore W1992756775C2781228144 @default.
• W1992756775 hasConceptScore W1992756775C2909179924 @default.
• W1992756775 hasConceptScore W1992756775C31760486 @default.
• W1992756775 hasConceptScore W1992756775C43376680 @default.
• W1992756775 hasConceptScore W1992756775C71924100 @default.
• W1992756775 hasConceptScore W1992756775C90924648 @default.
• W1992756775 hasIssue "5" @default.
• W1992756775 hasLocation W19927567751 @default.
• W1992756775 hasLocation W19927567752 @default.
• W1992756775 hasOpenAccess W1992756775 @default.
• W1992756775 hasPrimaryLocation W19927567751 @default.
• W1992756775 hasRelatedWork W1550484024 @default.
• W1992756775 hasRelatedWork W1963650660 @default.
• W1992756775 hasRelatedWork W2002783910 @default.
• W1992756775 hasRelatedWork W2005605711 @default.

• next